Brief: Anixa Biosciences Announces Commencement Of Phase 1B Trial Of Its Breast Cancer Vaccine
26/10/2022 14:12
Oct 26 (Reuters) - Anixa Biosciences Inc ANIX.O :
* ANIXA BIOSCIENCES ANNOUNCES COMMENCEMENT OF PHASE 1B TRIAL
OF
ITS BREAST CANCER VACCINE AT CLEVELAND CLINIC
* ANIXA BIOSCIENCES INC- STUDY IS ESTIMATED TO BE COMPLETED
BY END
OF 2023
Source text for Eikon: ID:nPn72J4Sqa
Further company coverage: ANIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine